Attached files
| file | filename |
|---|---|
| EX-99.1 - MAP Pharmaceuticals, Inc. | v211916_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 16, 2011
MAP
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
|
Delaware
|
001-33719
|
20-0507047
|
||
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
2400
Bayshore Parkway, Suite 200, Mountain View, CA
|
|
94043
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (650) 386-3100
(Former
Name or Former Address, if Changed Since Last Report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions ( see
General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On February 16, 2011, Steven A. Elms
tendered his resignation as a member and as Chair of the Board of Directors (the
“Board”) of MAP Pharmaceuticals, Inc. (the “Company”), effective as of February
16, 2011. The resignation of Mr. Elms did not involve a disagreement
with the Company.
Also on February 16, 2011, the Board
appointed Scott R. Ward, a current member of the Board, to succeed Mr. Elms in
the position of Chair.
The
Company issued a press release dated February 18, 2011 announcing the foregoing,
a copy of which press release is attached hereto as Exhibit 99.1, and
incorporated herein by reference.
|
Item 9.01
|
Financial
Statements and Exhibits
|
|
(d)
|
Exhibits
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press
Release of MAP Pharmaceuticals, Inc., dated February 18,
2011
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February
18, 2011
|
MAP
PHARMACEUTICALS, INC.
|
|||
|
By:
|
/s/
Charlene A. Friedman
|
||
|
Name:
|
Charlene
A. Friedman
|
||
|
Title:
|
Senior
Vice President, General Counsel and Secretary
|
||
INDEX
TO EXHIBITS FILED WITH
THE
CURRENT REPORT ON FORM 8-K DATED FEBRUARY 18, 2011
|
Exhibit
|
|
Description
|
|
99.1
|
|
Press
Release of MAP Pharmaceuticals, Inc., dated February 18,
2011
|